Unknown

Dataset Information

0

ARID1B alterations identify aggressive tumors in neuroblastoma.


ABSTRACT: Targeted panel sequencing was performed to determine molecular targets and biomarkers in 72 children with neuroblastoma. Frequent genetic alterations were detected in ALK (16.7%), BRCA1 (13.9%), ATM (12.5%), and PTCH1 (11.1%) in an 83-gene panel. Molecular targets for targeted therapy were identified in 16 of 72 patients (22.2%). Two-thirds of ALK mutations were known to increase sensitivity to ALK inhibitors. Sequence alterations in ARID1B were identified in 5 of 72 patients (6.9%). Four of five ARID1B alterations were detected in tumors of high-risk patients. Two of five patients with ARID1B alterations died of disease progression. Relapse-free survival was lower in patients with ARID1B alterations than in those without (p = 0.01). In analysis confined to high-risk patients, 3-year overall survival was lower in patients with an ARID1B alteration (33.3 ± 27.2%) or MYCN amplification (30.0 ± 23.9%) than in those with neither ARID1B alteration nor MYCN amplification (90.5 ± 6.4%, p = 0.05). These results provide possibilities for targeted therapy and a new biomarker identifying a subgroup of neuroblastoma patients with poor prognosis.

SUBMITTER: Lee SH 

PROVIDER: S-EPMC5542239 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


Targeted panel sequencing was performed to determine molecular targets and biomarkers in 72 children with neuroblastoma. Frequent genetic alterations were detected in ALK (16.7%), BRCA1 (13.9%), ATM (12.5%), and PTCH1 (11.1%) in an 83-gene panel. Molecular targets for targeted therapy were identified in 16 of 72 patients (22.2%). Two-thirds of ALK mutations were known to increase sensitivity to ALK inhibitors. Sequence alterations in ARID1B were identified in 5 of 72 patients (6.9%). Four of fiv  ...[more]

Similar Datasets

| S-EPMC3557959 | biostudies-literature
2015-10-21 | GSE73537 | GEO
| EGAS00001001479 | EGA
| EGAS00001000369 | EGA
| S-EPMC3855102 | biostudies-literature
| S-EPMC6804876 | biostudies-literature
| S-EPMC2742373 | biostudies-other
| S-EPMC7158874 | biostudies-literature
| S-EPMC4412512 | biostudies-literature
| S-EPMC3064691 | biostudies-literature